查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750857

人類乳突病毒 (HPV) 疫苗市場規模、佔有率、趨勢分析報告：按類型、疾病、分銷管道、地區、細分市場預測，2025-2030 年

Human Papillomavirus Vaccines Market Size, Share & Trends Analysis Report By Type (Bivalent, Quadrivalent, Nonavalent), By Disease (Cervical Cancer, Anal Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10個工作天內

價格

人類乳突病毒疫苗市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，預計到2030年全球人類乳突病毒疫苗市場規模將達到140.3億美元，2025-2030年期間的複合年成長率為8.82%。

各國政府和國際衛生組織擴大參與推廣人類乳突病毒(HPV)疫苗，這大大推動了市場成長。例如，2024 年 11 月，寮國人民民主共和國 (Lao-PDR)衛生署與聯合國兒童基金會、世界衛生組織 (WHO)、全球疫苗免疫聯盟 (Gavi) 合作，並在澳洲政府的支持下，正式啟動了 2024 年人類乳突病毒 (HPV) 疫苗宣傳活動。在全球疫苗免疫聯盟、世衛組織和泛美衛生組織等全球組織的資金支持下，許多國家已將人類乳突病毒(HPV)疫苗納入國家免疫計畫。這類合作正在擴大中低收入國家獲得疫苗的機會，幫助這些國家克服成本障礙和後勤挑戰。

此外，學校疫苗接種計畫在涵蓋青少年方面特別有效，青少年是HPV預防的主要目標族群。泛美衛生組織的循環基金和世界衛生組織對Cervavac和Walrinvax等新疫苗的核准程序也正在擴大可及的疫苗接種範圍。隨著越來越多的國家努力實現世界衛生組織消除子宮頸癌的目標， 人類乳突病毒(HPV)疫苗疫苗接種正成為國家戰略的支柱，推動公共和私營部門的需求，並創造巨大的市場機會。

提高全球對 HPV 感染、相關健康風險和疫苗接種益處的認知是推動市場成長的主要因素。公共衛生宣傳活動、社群媒體推廣和學校教育計畫在改變觀念和鼓勵疫苗接種方面發揮關鍵作用。在擁有強大醫療傳播策略的國家，如澳洲和英國， 人類乳突病毒(HPV)疫苗接種率明顯較高，這反映了持續的基於證據的提高認知工作的有效性。性別中立的疫苗訊息也提高了男性族群的接受度，特別是考慮到男性口咽癌和肛門癌的發生率不斷上升。隨著性健康恥辱感的消退和越來越多的人意識到疫苗接種的長期預防癌症益處，越來越多的人開始接種疫苗。這些提高意識的努力不僅增加了需求，而且還帶來了更早的疫苗接種、更高的遵從率和更穩定的市場成長。

全球 HPV 相關癌症（尤其是子宮頸癌）的盛行率不斷上升，是人類乳突病毒(HPV)疫苗市場強勁的成長動力之一。根據世界衛生組織 (WHO) 預測，2022 年子宮頸癌將成為女性第四大常見癌症，全球將導致超過 342,000 人死亡。約 95% 的子宮頸癌病例與持續感染高危險 HPV 類型有關，主要是 16 型和 18 型。同樣，其他 HPV 相關癌症（包括口咽癌、肛門癌、陰莖癌、陰道癌和外陰癌）的發生率也在上升，尤其是在高所得國家。例如，在美國，目前超過 70% 的口咽癌與 HPV 有關，而且這種趨勢在過去十年中穩步上升。日益加重的疾病負擔提升了人類乳突病毒(HPV)疫苗作為公共衛生挑戰的作用。隨著診斷和監測技術的進步以及 HPV 相關癌症數據變得更加豐富，迫切需要實施廣泛的疫苗接種策略，尤其是在青少年中，從而加速全球市場的需求。

人類乳突病毒疫苗市場報告重點

  • 按類型分類，四價疫苗預計將在2024年佔據75.67%的市場佔有率，因為它們對四種主要HPV類型——6、11、16和18——具有全面的保護作用。已知這四種類型的HPV導致近70%的子宮頸癌病例和近90%的生殖器濕疣，這使得四價疫苗成為全球HPV疫苗接種策略的關鍵組成部分。
  • 按疾病分類，子宮頸癌佔據市場主導地位，2024 年的收入佔有率為 63.78%。子宮頸癌是最常見的 HPV 相關惡性腫瘤之一，主要由 HPV 16 型和 18 型引起，約佔所有病例的 70%。
  • 從分銷通路來看，醫院和零售藥局預計將在2024年佔據最大佔有率，達到54.75%，並在預測期內以最快的速度成長。這一趨勢主要源自於這些醫療機構為尋求人類乳突病毒(HPV)疫苗的患者提供的日益便捷、可靠和便捷的接種體驗。
  • 到 2024 年，北美將以 39.83% 的佔有率引領全球市場，這得益於廣泛的疫苗接種覆蓋率、強力的公共衛生宣傳活動以及公共和私人醫療保健系統早期採用人類乳突病毒(HPV)疫苗，從而確保廣泛的人口保護。
  • 全球人類乳突病毒(HPV)疫苗市場的主要參與者包括默克公司、葛蘭素史克公司 (GSK) 和印度血清研究所私人有限公司。所有主要企業都在透過推出新產品、建立策略夥伴關係關係和擴展到新地區等策略來加強其在全球的地位。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 人類乳突病毒（HPV）疫苗市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場趨勢與展望
  • 市場動態
    • HPV相關癌症發生率不斷上升
    • 政府和非政府組織的疫苗接種計劃
    • 意識提升和教育活動
    • 醫療成本不斷上漲
    • 疫苗技術的進步
  • 市場限制因素分析
    • 疫苗成本高昂
    • 服務欠缺地區的認知度較低
    • 波特五力分析
    • PESTEL分析

4. 人類乳突病毒（HPV）疫苗市場類型、估值及趨勢分析

  • 人類乳突病毒（HPV）疫苗市場：類型變異分析
  • 按類型
  • 二價
  • 四價
  • 9價

第5章 人類乳突病毒 (HPV) 疫苗市場：按疾病、估計和趨勢分析

  • 人類乳突病毒（HPV）疫苗市場：疾病趨勢分析
  • 按疾病
  • 子宮頸癌
  • 陰道癌及外陰癌
  • 肛門癌
  • 口咽癌（頭頸癌）
  • 生殖器疣

6. 人類乳突病毒（HPV）疫苗市場通路預測及趨勢分析

  • 人類乳突病毒（HPV）疫苗市場：分銷管道波動分析
  • 按分銷管道
  • 醫院和藥房
  • 政府供應商
  • 其他

7. 人類乳突病毒 (HPV) 疫苗市場：區域、估計和趨勢分析

  • 2024 年和 2030 年人類乳突病毒 (HPV) 疫苗市場佔有率
  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 2018-2030年北美人類乳突病毒（HPV）疫苗市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年歐洲人類乳突病毒（HPV）疫苗市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年亞太地區人類乳突病毒（HPV）疫苗市場
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 南美洲
    • 2018-2030年南美人類乳突病毒（HPV）疫苗市場
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年中東和非洲人類乳突病毒（HPV）疫苗市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 戰略地圖
  • 2024年公司市場佔有率分析
  • 公司簡介
    • Merck &Co., Inc.
    • GlaxoSmithKline plc（GSK）
    • Serum Institute of India Pvt. Ltd.
    • Sanofi Pasteur SA
    • Pfizer Inc.
    • Inovio Pharmaceuticals Inc.
    • Walvax Biotechnology Co., Ltd.
    • Bharat Biotech International Ltd.
    • Johnson &Johnson Services, Inc.
    • Moderna, Inc.
    • Gilead Sciences, Inc.
Product Code: GVR-4-68040-578-3

Human Papillomavirus Vaccines Market Growth & Trends:

The global Human Papillomavirus vaccines market size is expected to reach USD 14.03 billion by 2030, registering a CAGR of 8.82% from 2025 to 2030, according to a new report by Grand View Research, Inc., driven by several key factors. The increasing involvement of governments and international health organizations in promoting HPV vaccination is significantly propelling market growth. For instance, in November 2024, the Ministry of Health of the Lao People's Democratic Republic (Lao PDR), in collaboration with UNICEF, the World Health Organization (WHO), and Gavi, the Vaccine Alliance-with support from the Government of Australia-officially launched the 2024 Human Papillomavirus (HPV) immunization campaign. Many countries have introduced HPV vaccines into their national immunization schedules, often with funding support from global organizations such as GAVI, WHO, and PAHO. These collaborations have expanded access to vaccines in low- and middle-income countries, helping overcome cost barriers and logistical challenges.

In addition, school-based vaccination programs have been particularly effective in reaching adolescent populations, which are the primary target for HPV prevention. The Pan American Health Organization's revolving fund and WHO's prequalification process for new vaccines like Cervavac and Walrinvax have also broadened the landscape of accessible options. As countries increasingly aim to meet the WHO's goal of eliminating cervical cancer, HPV vaccination is becoming a central pillar in their national strategies, boosting both public and private sector demand and creating significant market opportunities.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

The increasing global prevalence of HPV-related cancers, particularly cervical cancer, is one of the strongest growth drivers of the HPV vaccines market. According to the World Health Organization (WHO), in 2022, cervical cancer was responsible for over 342,000 deaths worldwide, making it the fourth most common cancer among women. Approximately 95% of cervical cancer cases are linked to persistent infection with high-risk HPV types, primarily types 16 and 18. Similarly, the incidence of other HPV-associated cancers-such as oropharyngeal, anal, penile, vaginal, and vulvar cancers-is on the rise, especially in high-income countries. For example, HPV is now responsible for over 70% of oropharyngeal cancers in the United States, a trend that has been steadily increasing over the past decade. This growing disease burden has elevated the role of HPV vaccination in public health agendas. With improved diagnostics and surveillance, and as HPV-related cancer data becomes more robust, the urgency to implement broad vaccination strategies, particularly for adolescents, is accelerating global market demand.

Human Papillomavirus Vaccines Market Report Highlights:

  • In 2024, the quadrivalent segment held the largest market share of 75.67%, attributed to its comprehensive protection against four major HPV types-6, 11, 16, and 18. These strains are known to cause nearly 70% of cervical cancer cases and about 90% of genital warts, making the quadrivalent vaccine a key component in HPV immunization strategies worldwide.
  • In 2024, the cervical cancer segment dominated the market, capturing a revenue share of 63.78%, driven by increased awareness and strong preventive measures. Cervical cancer is among the most prevalent HPV-related malignancies, primarily caused by HPV types 16 and 18, which are responsible for approximately 70% of all cases.
  • In 2024, the hospitals and retail pharmacies segment held the largest revenue share of 54.75% and is projected to experience the fastest growth during the forecast period. This trend is primarily driven by the growing accessibility, convenience, and reliability that these healthcare facilities offer to patients seeking HPV vaccination.
  • In 2024, North America led the global market with a share of 39.83%, fueled by extensive immunization coverage, robust public health campaigns, and early adoption of HPV vaccines across both public and private healthcare systems, ensuring broad population protection.
  • The global HPV vaccines market is led by several major companies, including Merck & Co., Inc., GlaxoSmithKline plc (GSK), Serum Institute of India Pvt. Ltd., among others. All key companies are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Disease
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Disease outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Human Papillomavirus (HPV) Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Rising prevalence of HPV-related cancers
    • 3.4.2. Government and NGO immunization programs
    • 3.4.3. Growing Awareness and education initiatives
    • 3.4.4. Increase in healthcare expenditure
    • 3.4.5. Advancements in vaccine technology
  • 3.5. Market Restraint Analysis
    • 3.5.1. High vaccine costs
    • 3.5.2. Limited Awareness in Underserved Regions
    • 3.5.3. Porter's Five Forces Analysis
    • 3.5.4. PESTEL Analysis

Chapter 4. Human Papillomavirus (HPV) Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Human Papillomavirus (HPV) Vaccines Market: Type Movement Analysis
  • 4.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Type
  • 4.3. Bivalent
    • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4. Quadrivalent
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Nonavalent
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Human Papillomavirus (HPV) Vaccines Market: Disease Estimates & Trend Analysis

  • 5.1. Human Papillomavirus (HPV) Vaccines Market: Disease Movement Analysis
  • 5.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Disease
  • 5.3. Cervical Cancer
    • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Vaginal and Vulvar Cancers
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Anal Cancer
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oropharyngeal (Head and Neck) Cancers
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Genital Warts
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Human Papillomavirus (HPV) Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Human Papillomavirus (HPV) Vaccines Market: Distribution Movement Analysis
  • 6.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Distribution Channel
  • 6.3. Hospitals and Retail Pharmacies
    • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Government Suppliers
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Human Papillomavirus (HPV) Vaccines Market: Regional Estimates & Trend Analysis

  • 7.1. Human Papillomavirus (HPV) Vaccines Market Share By Region, 2024 & 2030
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Regional Market Dashboard
  • 7.4. Global Regional Market Snapshot
  • 7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.6. North America
    • 7.6.1. North America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.2. U.S.
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. U.S. Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.3. Canada
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Canada Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.6.4. Mexico
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Mexico Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7. Europe
    • 7.7.1. Europe Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.2. UK
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. UK Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.3. Germany
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Germany Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.4. France
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. France Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.5. Italy
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Italy Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.6. Spain
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Spain Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.7. Denmark
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Denmark Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.8. Sweden
      • 7.7.8.1. Key Country Dynamics
      • 7.7.8.2. Competitive Scenario
      • 7.7.8.3. Regulatory Framework
      • 7.7.8.4. Sweden Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.7.9. Norway
      • 7.7.9.1. Key Country Dynamics
      • 7.7.9.2. Competitive Scenario
      • 7.7.9.3. Regulatory Framework
      • 7.7.9.4. Norway Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8. Asia Pacific
    • 7.8.1. Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.2. Japan
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Japan Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.3. China
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. China Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.4. India
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. India Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.5. Australia
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Australia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.6. Thailand
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Thailand Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.8.7. South Korea
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. South Korea Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9. Latin America
    • 7.9.1. Latin America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.2. Brazil
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. Brazil Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.9.3. Argentina
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Argentina Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10. MEA
    • 7.10.1. MEA Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.2. South Africa
      • 7.10.2.1. Key Country Dynamics
      • 7.10.2.2. Competitive Scenario
      • 7.10.2.3. Regulatory Framework
      • 7.10.2.4. South Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.3. Saudi Arabia
      • 7.10.3.1. Key Country Dynamics
      • 7.10.3.2. Competitive Scenario
      • 7.10.3.3. Regulatory Framework
      • 7.10.3.4. Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.4. UAE
      • 7.10.4.1. Key Country Dynamics
      • 7.10.4.2. Competitive Scenario
      • 7.10.4.3. Regulatory Framework
      • 7.10.4.4. UAE Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
    • 7.10.5. Kuwait
      • 7.10.5.1. Key Country Dynamics
      • 7.10.5.2. Competitive Scenario
      • 7.10.5.3. Regulatory Framework
      • 7.10.5.4. Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Strategy Mapping
  • 8.4. Company Market Share Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GlaxoSmithKline plc (GSK)
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Serum Institute of India Pvt. Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Sanofi Pasteur SA
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Inovio Pharmaceuticals Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Walvax Biotechnology Co., Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bharat Biotech International Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Johnson & Johnson Services, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Moderna, Inc.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Gilead Sciences, Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Table

  • Table 1 List of abbreviations
  • Table 2 Global Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 4 Global Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Human Papillomavirus (HPV) Vaccines Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 9 North America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 12 U.S. Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 15 Canada Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Mexico Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 18 Mexico Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Europe America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 22 Europe America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 UK Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 25 UK Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Germany Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 28 Germany Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 France Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 31 France Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Italy Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 34 Italy Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Spain Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 37 Spain Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Denmark Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 40 Denmark Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Sweden Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 43 Sweden Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 45 Norway Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 46 Norway Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 53 Japan Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 China Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 China Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 56 China Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 India Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 59 India Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Australia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 62 Australia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Thailand Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 65 Thailand Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 South Korea Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 South Korea Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 68 South Korea Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Latin America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 72 Latin America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 Brazil Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 75 Brazil Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 78 Argentina Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by type, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 85 South Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 88 audi Arabia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 91 UAE Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Human Papillomavirus (HPV) Vaccines Market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Human papillomavirus (HPV) vaccines market: Type movement analysis
  • Fig. 15 Human papillomavirus (HPV) vaccines market: Type outlook and key takeaways
  • Fig. 16 Bivalent market estimates and forecast, 2018 - 2030
  • Fig. 17 Quadrivalent market estimates and forecast, 2018 - 2030
  • Fig. 18 Nonavalent market estimates and forecast, 2018 - 2030
  • Fig. 19 Human papillomavirus (HPV) vaccines market: Disease movement analysis
  • Fig. 20 Human papillomavirus (HPV) vaccines market: Disease outlook and key takeaways
  • Fig. 21 Cervical Cancer market estimates and forecast, 2018 - 2030
  • Fig. 22 Vaginal and Vulvar Cancers market estimates and forecast, 2018 - 2030
  • Fig. 23 Anal Cancer market estimates and forecast, 2018 - 2030
  • Fig. 24 Oropharyngeal (Head and Neck) Cancers market estimates and forecast, 2018 - 2030
  • Fig. 25 Genital Warts market estimates and forecast, 2018 - 2030
  • Fig. 26 Human papillomavirus (HPV) vaccines market: Distribution channel movement analysis
  • Fig. 27 Human papillomavirus (HPV) vaccines market: Distribution channel outlook and key takeaways
  • Fig. 28 Hospitals and Retail Pharmacies market estimates and forecast, 2018 - 2030
  • Fig. 29 Government Suppliers market estimates and forecast, 2018 - 2030
  • Fig. 30 Others market estimates and forecast, 2018 - 2030
  • Fig. 31 Regional outlook, 2024 & 2030
  • Fig. 32 Global Human Papillomavirus (HPV) Vaccines Market: Region movement analysis
  • Fig. 33 North America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 39 UK Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 40 France Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 48 China Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 49 India Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)